v3.26.1
Segment, Geographic and Other Revenue Information (Tables)
 6 Months Ended
Jun. 28, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Segment
The following provides selected information by reportable segment:
Three Months Ended
Total Revenues
Earnings(a)
Depreciation and Amortization(b)
(MILLIONS)June 28,
2026		June 29,
2025		June 28,
2026		June 29,
2025		June 28,
2026		June 29,
2025
Reportable Segment:
Biopharma(c)
$14,661 $14,305 $6,887 $6,891 $324 $339 
Other business activities(d)
373 348 (1,708)(1,762)105 73 
Reconciling Items:
Amortization of intangible assets(1,185)(1,211)1,185 1,211 
Acquisition-related items(669)(338)(2)(2)
Certain significant items(e)
(3,978)(537)10 3 
$15,034 $14,653 $(653)$3,044 $1,622 $1,625 
Six Months Ended
Total Revenues
Earnings(a)
Depreciation and Amortization(b)
(MILLIONS)June 28,
2026		June 29,
2025		June 28,
2026		June 29,
2025		June 28,
2026		June 29,
2025
Reportable Segment:
Biopharma(c)
$28,822 $27,746 $13,725 $13,960 $672 $671 
Other business activities(d)
662 622 (3,376)(3,146)183 147 
Reconciling Items:
Amortization of intangible assets(2,368)(2,421)2,368 2,421 
Acquisition-related items(1,173)(620)(2)(3)
Certain significant items(e)
(4,291)(1,944)14 7 
$29,484 $28,367 $2,517 $5,828 $3,235 $3,243 
(a)Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). Effective in the third quarter of 2025, certain expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $38 million in the second quarter of 2025 and $74 million in the first six months of 2025 from Other business activities to Biopharma to conform to the current period presentation.
(b)Certain production facilities are shared. Depreciation is allocated based on estimates of physical production.
(c)Biopharma’s earnings include dividend income from our previous investment in ViiV of $98 million in the second quarter of 2026 and $73 million in the second quarter of 2025, and $180 million in the first six months of 2026 and $111 million in the first six months of 2025 recorded in Other (income)/deductions––net. Biopharma’s earnings in the first six months of 2025 also reflected a credit to Cost of Sales representing a favorable revision of our estimate of accrued royalties.
(d)Other business activities include revenues and costs associated with PC1 and our former operating segment, Pfizer Ignite, as well as costs that we do not allocate to our operating segments, per above.
(e)Earnings in the second quarter and the first six months of 2026 includes, among other things, (i) certain asset impairments of $4.3 billion recognized in the second quarter of 2026 and (ii) charges for certain legal matters of $842 million and $1.0 billion for the second quarter and the first six months of 2026, respectively, partially offset by (iii) a net gain of $1.870 billion from the sale of our previous investment in ViiV recognized in the second quarter of 2026 (items (i) through (iii) recorded in Other (income)/deductions––net) and (iv) restructuring charges/(credits), inventory write-offs, implementation costs and additional depreciation—asset restructuring of $591 million and $717 million for the second quarter and the first six months of 2026, respectively (primarily recorded in Restructuring charges and certain acquisition-related costs). Earnings in the first six months of 2025 included, among other items, (i) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $670 million (primarily recorded in Restructuring charges and certain acquisition-related costs) and (ii) charges for certain legal matters of $564 million recorded in Other (income)/deductions––net. See Notes 3 and 4.
The following provides Biopharma reportable segment information regularly provided to the CODM:
Three Months EndedSix Months Ended
(MILLIONS)June 28,
2026		June 29,
2025		June 28,
2026		June 29,
2025
Biopharma reportable segment:
Biopharma total revenues$14,661 $14,305 $28,822 $27,746 
Less:
Cost of sales3,188 3,075 6,222 5,389 
Selling, informational and administrative expenses2,344 2,343 4,475 4,529 
Research and development expenses2,376 2,109 4,513 4,050 
Acquired in-process research and development expenses16 2 153 11 
Other (income)/deductions––net(151)(115)(267)(193)
Biopharma earnings$6,887 $6,891 $13,725 $13,960 
The following provides additional revenue information for several of our major products:
(MILLIONS)Three Months EndedSix Months Ended
PRODUCTPRIMARY INDICATION OR CLASSJune 28,
2026		June 29,
2025		June 28,
2026		June 29,
2025
TOTAL REVENUES$15,034 $14,653 $29,484 $28,367 
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(a)
$14,661 $14,305 $28,822 $27,746 
Primary Care$5,503 $5,535 $11,046 $11,226 
Eliquis(b)
Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism2,425 2,003 4,591 3,926 
Prevnar family
Active immunization to prevent pneumonia, invasive disease and otitis media caused by Streptococcus pneumoniae
1,337 1,383 3,027 3,043 
Nurtec ODT/VyduraAcute treatment of migraine and prevention of episodic migraine421 359 774 607 
ComirnatyActive immunization to prevent COVID-19261 381 493 945 
Abrysvo
Active immunization to prevent RSV infection
208 143 388 274 
FSME-IMMUN/TicoVacActive immunization to prevent tick-borne encephalitis disease132 109 213 172 
Paxlovid
COVID-19 in certain high-risk patients21 427 207 918 
All other Primary CareVarious699 731 1,353 1,340 
Oncology$4,165 $4,034 $7,991 $7,528 
IbranceHR-positive/HER2-negative metastatic breast cancer and first-line maintenance treatment for adults with HR+, HER2+ locally advanced or metastatic breast cancer1,058 1,049 2,066 2,026 
Padcev
Locally advanced or metastatic urothelial cancer and cisplatin-ineligible/decline MIBC667 542 1,258 967 
Xtandi(c)
mCRPC, nmCRPC, mCSPC, nmCSPC534 566 978 1,023 
LorbrenaALK-positive metastatic NSCLC354 251 659 473 
(MILLIONS)Three Months EndedSix Months Ended
PRODUCTPRIMARY INDICATION OR CLASSJune 28,
2026		June 29,
2025		June 28,
2026		June 29,
2025
InlytaAdvanced renal cell carcinoma218 243 433 462 
Braftovi/Mektovi
Metastatic melanoma in patients with a BRAFV600E/K mutation and for metastatic NSCLC in patients with a BRAFV600E mutation; and, for Braftovi for the treatment of BRAFV600E-mutant mCRC, in combination with Erbitux® (cetuximab)(d) (after prior therapy) or cetuximab and fluorouracil-based chemotherapy
223 182 398 317 
Adcetris(e)
Certain lymphomas including classical Hodgkin lymphoma, T-cell lymphoma and relapsed/refractory diffuse large B-cell lymphoma
196 255 386 472 
TukysaUnresectable or metastatic HER2-positive breast cancer; RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer138 132 259 234 
Orgovyx(f)
Advanced prostate cancer
146 97 255 173 
BosulifPhiladelphia chromosome–positive chronic myelogenous leukemia113 149 242 300 
Elrexfio
Relapsed or refractory multiple myeloma
89 85 169 145 
Talzenna
Treatment of BRCA gene-mutated, HER2-negative, inoperable or recurrent breast cancer; and, in combination with Xtandi (enzalutamide), of adult patients with HRR gene-mutated mCRPC
57 46 107 86 
Tivdak
Recurrent or mCC with disease progression on or after chemotherapy
34 46 67 79 
All other Oncology
Various338 394 713 771 
Specialty Care$3,353 $3,089 $6,292 $5,705 
Vyndaqel familyATTR-CM and polyneuropathy1,762 1,615 3,364 3,101 
XeljanzRA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis251 322 431 450 
Zavicefta (Outside the U.S. and Canada)Bacterial infections199 163 350 299 
Enbrel (Outside the U.S. and Canada)RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis142 154 280 294 
Octagam
Primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in adults, and dermatomyositis in adults
138 96 260 184 
CresembaInvasive aspergillosis and mucormycosis106 111 194 184 
GenotropinReplacement of human growth hormone94 106 187 201 
CibinqoAtopic dermatitis94 69 171 127 
All other Specialty CareVarious566 453 1,056 866 
Hospital and Biosimilars(a)
$1,640 $1,647 $3,494 $3,286 
Oncology biosimilars(g)
Various
359 353 768 617 
InflectraCrohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis171 139 353 291 
Sulperazon (Outside the U.S. and Canada)
Bacterial infections116 166 315 330 
ZithromaxBacterial infections42 56 154 213 
All other Hospital and Biosimilars
Various
952 934 1,905 1,835 
PFIZER CENTREONE(h)
$373 $348 $662 $622 
BIOPHARMA(a)
$14,661 $14,305 $28,822 $27,746 
PFIZER U.S. COMMERCIAL DIVISION
7,956 8,011 15,642 15,583 
PFIZER INTERNATIONAL COMMERCIAL DIVISION
5,544 5,178 10,777 10,027 
GLOBAL HOSPITAL AND BIOSIMILARS DIVISION(i)
1,161 1,116 2,403 2,136 
Total Alliance revenues included above$2,697 $2,273 $5,036 $4,386 
Total Royalty revenues included above
$474 $426 $870 $734 
(a)In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. See Note 13A above. We reclassified prior period amounts to conform to the current period presentation.
(b)Reflects alliance revenues and product revenues.
(c)Primarily reflects alliance revenues and royalty revenues.
(d)Erbitux® is a registered trademark of ImClone LLC.
(e)Reflects product revenues and royalty revenues.
(f)Reflects alliance revenues.
(g)Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Zirabev, Retacrit, Trazimera and Nivestym.
(h)PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships. Also includes revenues associated with the wind-down of our former Pfizer Ignite operating segment, which were not material in all periods presented. We reclassified prior period amounts to conform to the current period presentation.
(i)See Note 13A above.
Schedule of Revenues by Geographic Region
The following summarizes revenues by geographic area:
Three Months EndedSix Months Ended
(MILLIONS)June 28,
2026		June 29,
2025		June 28,
2026		June 29,
2025
United States$8,857 $8,894 $17,588 $17,268 
International:
Developed Markets
3,743 3,393 7,169 6,571 
Emerging Markets2,434 2,366 4,727 4,529 
Total revenues
$15,034 $14,653 $29,484 $28,367